
Opinion|Videos|July 2, 2024
Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.
Advertisement
Episodes in this series

- Which agents do we have to target abnormalities in gut-liver axis to prevent and treat HE? (lactulose or lactitol, rifaximin)
Sanchez-Delgado et al 2016 - What is the mechanism of action of these therapies?
- What is their tolerability and their side effect profile?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
OMA 2026 Recap: GLP-1s in Conditions Beyond Obesity
3
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
4
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
5





































































